Crimean-Congo hemorrhagic fever virus (CCHFV; genus Nairovirus) is an extremely pathogenic member of the Bunyaviridae family. Since handling of the virus requires a biosafety level 4 (BSL-4) facility, little is known about pathomechanisms and host interactions. Here, we describe the establishment of a transcriptionally competent virus-like particle (tc- 
cellular proteins, and the function of viral protein domains (8) . The most elementary setup, the minireplicon system, is based on the expression of an artificial, genome-like reporter RNA flanked by viral UTRs, which is encapsidated by recombinant N and L proteins to be transcribed and replicated. Minireplicon systems have been developed for several bunyaviruses, namely, Bunyamwera virus (9) , Uukuniemi virus (10), Hantaan virus (HTNV) (11) , Rift Valley fever virus (RVFV) (12) , La Crosse virus (LACV) (13) , and, recently, CCHFV (14) . Minireplicon systems have helped the understanding of specific aspects of the viral cycle, such as transcription and encapsidation of the viral genome (15) (16) (17) . Additional information, however, can be obtained by expanding to a system for transcriptionally competent virus-like particles (tc-VLPs) (8) . Hereby, expression of viral glycoproteins (GPs) in addition to the minireplicon components leads to self-assembly into tc-VLPs, which structurally and functionally mimic the parental virus. Since VLPs are devoid of viral coding sequences, they cannot propagate and hence represent a safe tool to study highly pathogenic viruses under less-stringent-biosafety-level conditions (8, (18) (19) (20) . Here, we describe the establishment of a tc-VLP system for CCHFV and demonstrate its potential to reconcile and investigate viral entry, primary transcription, genome replication, particle propagation, and antibody neutralization. Moreover, the system allowed us to confirm the previously hypothesized location (21) of the CCHFV endonuclease domain within the L protein.
MATERIALS AND METHODS

Cells and viruses.
HuH-7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), 1% L-glutamine, and 1% penicillin-streptomycin. SW-13 cells were grown in Rega 3 minimum essential medium (MEM) (Life Technologies), 1% Lglutamine, 1% penicillin-streptomycin, and 0.00075% sodium bicarbonate. CCHFV strain IbAr10200 was propagated on SW-13 cells under BSL-4 conditions.
Plasmids. The constructs encoding wild-type (wt) and RdRp-inactive CCHFV L polymerase (pCAGGS_V5_L_wt and pCAGGS_V5_L_⌬DD), CCHFV N nucleoprotein (pCAGGS_N), CCHFV-specific Gaussia luciferase minigenome (T7-vS-Gluc and T7-vL-Gluc), T7 polymerase (pCAGGS_T7), and negative-control protein (pcDNA3.1_3ϫFlag_ ⌬Mx) were described previously (14, 22) . The plasmids pGL3-luc and pRL-SV40, constitutively expressing firefly luciferase (FF-Luc) or Renilla luciferase (REN-Luc), respectively, were purchased from Promega.
All other plasmids were generated using standard molecular cloning techniques and confirmed by DNA sequencing. PCR was carried out with the Phusion HotStartII enzyme (FinnZymes). Plasmid pCAGGS_GP was constructed by subcloning the CCHFV major open reading frame (M-ORF) (23) into pCAGGS. The two genomic T7 polymerase (pol)-driven constructs pT7riboSM2_vS_Ren and pT7riboSM2_vL_Ren contain the REN-Luc gene in antisense orientation, flanked by the 3= and 5= genomic untranslated regions (promoter) of the CCHFV S and L segments, respectively. Those plasmids were obtained by a two-step method. In the first step, the CCHFV minigenome sequences vS_Gluc and vL_Gluc, encoding Gaussia luciferase in antisense orientation, were amplified by PCR from plasmids T7-vS-Gluc and T7-vL-Gluc (14), respectively. Restriction sites for Esp3I were engineered into the forward and reverse primers, to generate ends that are compatible with plasmid pT7riboSM2 (24) cut by the same enzyme. After ligation, the plasmids pT7riboSM2_vS_Gluc and pT7riboSM2_vL_Gluc were obtained. In a second step, the Gaussia reporter gene was replaced by the REN-Luc gene. Plasmid pRL-SV40 served as the PCR template for the REN-Luc sequence, using forward and reverse primers that contained restriction sites for BglII and KpnI, respectively. Both the PCR product and the recipient plasmids pT7riboSM2_vS_Gluc and pT7RiboSM2_vL_Gluc were cleaved with these enzymes. The insert containing the Gaussia luciferase gene was discarded, and the PCR fragment with the REN-Luc sequence was inserted into the vector backbone. The resulting plasmids pT7riboSM2_vS_Ren and pT7riboSM2_vL_Ren contained the REN-Luc gene in antisense orientation flanked by promoter sequences of CCHFV S and L segments, respectively.
Plasmid constructs pCAGGS_V5_L_D693A, pCAGGS_V5_L_ D718A, and pCAGGS_V5_L_K734A, expressing mutated CCHFV polymerase sequences, were obtained by site-directed mutagenesis and cDNA cloning as follows. Three overlapping PCR products were separately amplified using the pCAGGS_V5_L_wt plasmid as the template. The overlapping PCR products covered the region between the BstBI and PacI sites of the L sequence and contained either mutation D693A, D718A, or K734A, introduced by the respective primers (sequences available upon request). The three PCR fragments were combined and PCR reconstituted to a full-length product by using the flanking primers only. The DNA was then digested with BstBI and PacI and cloned into pCAGGS_V5_L_wt which was cut with the same enzymes. Sequencing of the full-length L sequences was carried out to confirm the individual point mutations and to rule out any other unspecific mutations.
Production and amplification of tc-VLPs expressing Renilla luciferase. Subconfluent monolayers of HuH-7 cells ("donor cells") seeded in 6-well plates were transfected with 600 ng of pCAGGS_V5_L (_wt or _⌬DD), 200 ng of pCAGGS_N, 200 ng of pT7riboSM2_vS_Ren or pT7riboSM2_vL_Ren, 500 ng of pCAGGS_GP, 500 ng of pCAGGS_T7, and 100 ng of pGL3-Luc control, using Nanofectin transfection reagent (PAA Laboratories). The pGL3-Luc was cotransfected as a marker for potential carryover transfection of indicator cells. Depending on the specific experimental setup, some plasmids were omitted from the transfection mix. Four hours after transfection, the transfection medium was replaced with fresh medium. Cell supernatants were collected 72 h posttransfection, and REN-Luc and FF-Luc activities were measured in cell lysates using the dual-luciferase reporter assay system (Promega) and a Centro LB 960 microplate luminometer (Berthold Technologies). The supernatants were treated with 25 U/ml Benzonase (Novagen) at 37°C for 3 h and centrifuged at 12,000 ϫ g for 5 min to remove cellular debris. The presence of tc-VLPs in donor cell supernatant was validated by infecting HuH-7 cells ("indicator cells"). Briefly, HuH-7 cells grown in 6-well plates were washed with phosphate-buffered saline (PBS) and incubated with donor cell supernatants for 1 h at 37°C before fresh medium containing FCS was added. Luciferase activities were measured 24 h later as described above. In some experiments, indicator cells were pretransfected 20 h before supernatant transfer with 600 ng pCAGGS_V5_L_wt and 200 ng pCAGGS_N.
Amplification of tc-VLPs was conducted by transfer of cell supernatants (named passage n) onto new HuH-7 cells that were pretransfected 20 h earlier with 600 ng pCAGGS_V5_L_wt, 200 ng pCAGGS_N, and 500 ng pCAGGS_GP. Supernatants from passage n ϩ 1 were collected 72 h later and processed as described above.
Freshly produced supernatants were used, unless specified otherwise in the text.
Immunoblotting of tc-VLP content. The protein content of tc-VLPs was assessed by Western blotting, using CCHFV strain IbAr10200 as a control. CCHF tc-VLPs were produced in HuH-7 cells in T75 flasks by proportionally increasing the number of cells and plasmid amounts according to the flask surface. Corresponding control supernatants, from mock-and minireplicon (LϩN)-transfected HuH-7 cells, were also produced. CCHFV was amplified on SW-13 cells infected at a multiplicity of infection (MOI) of 0.01, and supernatant was collected 3 days postinfection (p.i.) (T75 flasks). A corresponding SW-13 mock control was also produced. Supernatants were prepared as follows: clarification from cell debris by centrifugation for 5 min at 500 ϫ g and concentration by ultracentrifugation through a 20% sucrose cushion at 28,000 rpm, for 2 h at 4°C, using an SW-32 rotor (Beckman). Pellets were dried for 10 min at room temperature before resuspension in Opti-MEM (Life Technologies). All lysates were prepared as follows: cells were scraped off in 10 ml PBS and centrifuged for 5 min at 500 ϫ g, and the pellet was resuspended in 150 l radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris HCl, pH 7.5, 15 mM NaCl, 1% NP-40) containing protease inhibitors (Roche). Supernatants and cell lysate samples were mixed with 4ϫ sample buffer (143 mM Tris-HCl, pH 6.8, 4.7% SDS, 28.6% glycerol, 20% ␤-mercaptoethanol, 4.3 mM bromophenol blue) and incubated for 10 min at 105°C. Proteins were analyzed by Western blotting (10% SDS-PAGE gel), using rabbit polyclonal antibodies against CCHFV N (1:5,000), CCHFV Gn (1:400), or CCHFV Gc (1:400) (25) . Staining of the blot with 0.1% Ponceau S in 5% acetic acid served as a loading control. A horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody (Thermo Fisher) (1:20,000) was used to detect the primary antibodies. Quantification of the signals was performed using the Image Lab 4.0 software.
VLP neutralization assay. Human serum neutralizing CCHFV was kindly donated by G. Korukluoglu (Refik Saydam National Public Health Agency, Ankara, Turkey). Sheep and mouse antisera raised against RVFV strain MP12 were kindly provided by A. Brun (INIA, Spain). The human control serum was kindly provided by A. Kaufmann (Philipps-University Marburg, Institute for Immunology, Germany). CCHF tc-VLPs were incubated for 1 h at 37°C with antisera diluted 1:200. HuH-7 cells, grown in 6-well plates and pretransfected with 600 ng of pCAGGS_V5_L_wt and 200 ng of pCAGGS_N, were infected with the treated tc-VLP-containing supernatants. Luciferase activity was measured 24 h postinfection as described above.
Titration of CCHF tc-VLPs by immunofluorescence staining. Subconfluent monolayers of HuH-7 cells grown on coverslips were transfected with 600 ng of pCAGGS_V5_L_wt and 200 ng of pCAGGS_N, as described above. After overnight incubation at 37°C, the cells were infected with 10-fold dilutions of tc-VLP-containing supernatants. Twenty hours later, cells were fixed in 4% paraformaldehyde for 10 min, permeabilized with 0.2% Triton X-100 for 5 min, and blocked with PBS containing 2.5% FCS for 30 min. Rabbit polyclonal antibody against Renilla luciferase (MBL), diluted 1:200 in 2.5% FCS-PBS, was incubated for 30 min at room temperature, washed twice with PBS, and followed by an incubation with Alexa Fluor 488 donkey anti-rabbit IgG (Molecular Probes), diluted 1:400 in 2.5% FCS-PBS, for 30 min at room temperature (RT). Cell nuclei were counterstained with 4=,6-diamidino-2-phenylindole (DAPI) (1 g/ml) for 5 min at room temperature. Images were obtained with a Zeiss Axiovert 200M microscope. Cell nuclei and Renilla luciferase-positive cells were counted in 4 random fields per condition, and titers were calculated accordingly.
Purification, stability, and cryoprotection assays. Freshly produced CCHFV tc-VLPs were treated with 25 U/ml Benzonase (Novagen) at 37°C for 3 h, centrifuged at 12,000 ϫ g for 5 min to remove cellular debris, and aliquoted.
Three methods were tested for tc-VLP purification and concentration: ultracentrifugation, ultracentrifugation through a sucrose cushion, and polyethylene glycol (PEG) precipitation. Ultracentrifugation (with or without a sucrose cushion) was conducted as described above for CCHFV particles. CCHFV tc-VLPs were also concentrated by polyethylene glycol precipitation. Briefly, a solution of 30% PEG 8000 (Sigma-Aldrich) was made in NTE buffer (100 mM NaCl, 10 mM Tris, pH 6.5, 1 mM EDTA). Cleared supernatants containing tc-VLPs were mixed with the PEG 8000 solution at a 10% final concentration and NaCl at a 230 mM final concentration. After a 30-min incubation with rocking at 4°C, samples were centrifuged for 1 h at 6,500 ϫ g and 4°C. In the 3 methods, the pellets containing tc-VLPs were resuspended in Opti-MEM (Life Technologies), to be 100-fold concentrated. For luciferase assays, concentrated tc-VLPs were diluted 1:100 in Opti-MEM before infection of indicator cells.
For stability assays, the freshly produced tc-VLP samples were either boiled for 10 min at 95°C or stored for 3 days at 37°C, room temperature (RT), 4°C, Ϫ20°C, or Ϫ80°C. Samples were also frozen (Ϫ80°C) and thawed (RT) three times or kept at Ϫ80°C for 1 year. For cryoprotection assays, aliquots were frozen either crude or in the presence of various and kept for 3 days at Ϫ20°C or Ϫ80°C or frozen-thawed 3 times. All additive solutions were previously sterilized with 0.22-m polyethersulfone filters (Sarstedt). Preservation of the different tc-VLP preparations was assessed by infection of HuH-7 cells pretransfected with 600 ng of pCAGGS_V5_L_wt and 200 ng of pCAGGS_N. Luciferase activity was measured 24 h later as described above and compared to freshly prepared, crude tc-VLP activity.
tc-VLP assay with endonuclease-inactive mutant polymerases. CCHFV tc-VLPs were produced as described above, using different polymerase constructs (pCAGGS_V5_L_⌬DD, _wt, _D693A, _D718A, or _K734A). HuH-7 cells, grown in 6-well plates and pretransfected with 600 ng of pCAGGS_V5_L_wt and 200 ng of pCAGGS_N, were infected with Benzonase-treated tc-VLP-containing supernatants. Luciferase activity was measured 24 h postinfection as described above.
Real-time RT-PCR. Protocols and primers for real-time reverse transcription-PCR (RT-PCR) were previously described (22) .
Statistics. The two-tailed, paired Student t test was used to compare the different conditions. The P value was considered significant if below 0.05.
RESULTS
Generation of CCHF virus-like particles expressing a reporter gene.
For our attempts to generate tc-VLPs for CCHFV, we built on the previously established minireplicon system (14) . The original minireplicon system consists of BSR-T7/5 cells transiently transfected with constructs for CCHFV L and N and an in vitrotranscribed RNA representing a CCHFV minigenome harboring a Gaussia luciferase gene. However, Gaussia luciferase is a secreted reporter and hence not suitable to monitor VLP activity in supernatants of transfected cells. Therefore, we replaced it with the cellbound Renilla luciferase (REN-Luc) reporter. We created two minigenome constructs, vS-Ren and vL-Ren, which contain the REN-Luc gene in negative-sense orientation, flanked by viral promoters of the CCHFV S and L segments, respectively. Coexpression of the viral glycoproteins (GPs) should enable packaging of the minireplicon RNPs into VLPs (Fig. 1A) , as was shown elsewhere for several other viruses (8) . Initial attempts with a series of cell lines (hamster BSR-T7/5, human HEK 293 and SW-13, and primate CV-1 and Vero) failed to yield detectable activity indicative of tc-VLPs, but the human hepatoma cell line HuH-7 turned out to be a reliable system. Curiously, in these cells the minireplicon system (i.e., expression of minigenome, L, and N) had very little activity over the background set by the transcriptionally inactive L mutant (L⌬DD), but addition of the GP construct led to strong reporter activity (Fig. 1B and D) . Experiments employing a neutralizing antibody showed that the GP-mediated boost (which was also observed for LACV and RVFV systems, though in a less extreme manner [18, 22] ) is due to reinfection of transfected cells by the generated VLPs (data not shown). Differently from the previously published minireplicon system (14), we obtained very little background activity by the minigenome plasmid if transfected without L polymerase (data not shown). The supernatants of the transfected HuH-7 cells ("donor cells") were harvested after 72 h of incubation and transferred onto fresh cells expressing CCHFV L and N ("indicator cells"). Measurement of REN-Luc activity 24 h later suggested formation of tc-VLPs derived from the full set of VLP plasmids ( Fig. 1C and E) . As expected, supernatants from the negative controls (inactive L mutant and minireplicon system only) did not yield substantial activities in indicator cells. Of note, usage of the L segment promoter for the REN-Luc mini-replicon resulted in approximately 50-fold-higher activity than that with the S segment promoter (compare Fig. 1C and E) . It was therefore decided to use the L segment-derived minireplicon for subsequent experiments.
CCHF VLPs have characteristics of the parental virus. So far, we have failed to visualize our tc-VLPs by immunoelectron microscopy, probably because of their inherent physical instability (see below) and the lack of a suitable antiserum. To obtain other, independent evidence of their composition, we analyzed the viral proteins present in tc-VLPs. Supernatants from HuH-7 cells transfected with different plasmid combinations were concentrated and purified by ultracentrifugation through a sucrose cushion and analyzed by Western blotting. As a control, we used supernatants of mock-and CCHFV-infected SW-13 cells, which were processed in the same way ( Fig. 2A, lanes 1 and 2) . As expected, no viral protein can be detected in mock-and untrans- fected cells (Fig. 2A, lanes 1 and 3) . The CCHFV glycoproteins Gn and Gc, as well as nucleoprotein N, can be detected approximately at their expected size (37, 75 , and 54 kDa, respectively) in both virus and tc-VLP supernatants ( Fig. 2A, lanes 2 and 6) . Interestingly, all these viral proteins are also found in concentrated supernatants from the control cells expressing an RdRp-inactive polymerase (L⌬DD) (Fig. 2A, lane 4) . Moreover, transfection of the GP plasmid alone is sufficient to secrete Gn and Gc in the supernatant (data not shown). Thus, VLPs can be produced in the absence of viral replication. However, as shown in Fig. 1C and E, L⌬DD VLPs seem to not have packaged authentic nucleocapsids, as they cannot be transcomplemented in indicator cells. Of note, supernatants from minireplicon-transfected cells contained spurious amounts of N, as demonstrated by the faint signal in the immunoblot (Fig. 2A, lane 5) . This confirms previous observations for CCHFV and RVFV that N can be secreted independently of GP (26, 27) . Nonetheless, the signals for N and the GPs are stronger in the supernatants containing tc-VLPs. A ratio among N, Gc, and Gn representation in concentrated CCHFV particles, empty VLPs, and tc-VLPs was made based on the band signal intensities of 3 independent immunoblotting experiments (Fig.  2B ). This semiquantitative method did not reveal significant differences in protein ratios between the different particle types, suggesting that tc-VLPs have a protein composition similar to that of authentic virions.
We also tested neutralization by specific antisera. The tc-VLPs were incubated either with two different antisera reactive against RVFV, with a human control antiserum, or with a human antiserum derived from a CCHFV-infected patient. Indicator cells expressing L and N were infected with the antiserum-pretreated tcVLPs, and reporter activities were measured as outlined above. Neutralization of tc-VLP activity was specific for the CCHFV antiserum (Fig. 2C) . Thus, our VLPs have antigenic properties of the parental CCHFV particles.
Increasing VLP production. Compared to systems for other bunyaviruses like LACV and RVFV (18, 22) , the reporter activity of the CCHFV tc-VLPs is rather low (data not shown). One measure to obtain a robust VLP system was to employ the minireplicon with the stronger L promoter (Fig. 1) . Moreover, we devised a strategy to increase particle yields. Repeated passaging on cells expressing the virus structure proteins, i.e., L, N, and the GPs, is expected to enable the replication and encapsidation of the VLPborne minireplicon RNA and the packing into second-generation progeny particles (Fig. 3A) . Indeed, in indicator cells the addition 6) were analyzed by Western blotting using polyclonal antibodies specific for CCHFV glycoprotein Gn (top panels), glycoprotein Gc (second panels), or nucleoprotein N (third panels). One representative blot of 3 is shown. (B) Ratios of N, Gc, and Gn expression in CCHFV, L⌬DD VLPs, and L VLPs, based on band intensities in 3 independent Western blotting experiments performed with ultracentrifuged supernatants. The two-tailed, paired t test did not show any significant differences among virus, empty VLPs, and L VLPs. (C) Neutralization of tc-VLPs by CCHFV-specific antisera. tc-VLPs were generated as described for Fig. 1 , using the L segment promoter minigenome (vL-Ren). The crude tc-VLP supernatants were incubated for 1 h at 37°C with human CCHFV-specific antiserum at a final dilution of 1:200. As controls, normal human serum was used, as well as sheep and mouse sera specific for RVFV. HuH-7 indicator cells were pretransfected with CCHFV L and N plasmids and infected with the different tc-VLP preparations. REN-Luc activity was measured 24 h postinfection, and the activity was normalized on the inactive L polymerase (L⌬DD) supernatant condition. Luciferase fold activation is shown only for tc-VLP-containing supernatants. Mean values and the standard deviations of 3 independent experiments are shown. A two-tailed, paired t test was used to compare the treated supernatants with the untreated one (no serum). *, P Ͻ 0.05; n.s., not significant. of a GP construct to the mix of support plasmids leads to a slight increase in reporter activity, suggesting formation and spreading of daughter particles (Fig. 3B, passage 0) . This difference between nucleocapsid amplification (N and L expression) and VLP amplification (N, L, and GP expression) was even more apparent when indicator cells were incubated for longer times. At 72 h postinfection, VLP activity was decreased if only N and L were provided in trans, whereas it increased when GPs were provided in addition (compare Fig. 3B , passage 0, with Fig. 3C, passage 0) . When VLP supernatants were further passaged on indicator cells, each step further increased reporter activities, suggesting efficient VLP amplification (Fig. 3B) . The increased VLP yields are also reflected by a weak but measurable primary transcription, i.e., VLP reporter activity in the absence of coexpressed L and N proteins (Fig. 3B,  passages 1 and 2, left columns) .
To determine the actual VLP titers after each passage, we employed immunofluorescence. Indicator cells expressing L and N were incubated with 10-fold dilutions of tc-VLP-containing supernatants collected 72 h postinfection and analyzed 24 h later by immunostaining against REN-Luc. Similar to the VLP reporter activity, the titers, which were calculated from the number of REN-Luc-positive cells (Fig. 3D) , demonstrate that repeated passaging is a useful method to optimize VLP production. Despite repeated attempts and further passaging, however, we were unable to produce VLP yields above approximately 10E5 particles per ml, possibly an underestimate caused by the comparatively low RENLuc production by the CCHFV promoter.
Importantly, the passaging strategy allows us to recapitulate all steps of the viral replication cycle under non-BSL-4 conditions. The preparations with increased titer that were obtained after several passages can detectably infect naive cells, thereby enabling the study of particle attachment, entry, and primary transcription. The passaging of tc-VLPs on cells expressing L, N, and GP extends the infection cycle to the subsequent steps of genome replication, secondary transcription, and particle assembly and release.
Stability of CCHF tc-VLPs. To obtain concentrations higher than the 10E5 particles per ml from the repeated passaging, we precipitated VLPs with polyethylene glycol (PEG) or ultracentrifuged them through a sucrose cushion. This allowed a further 10-to 100-fold concentration of VLP stocks (Fig. 4A) . Ultracentrifugation without a sucrose cushion, by contrast, resulted in a significant loss of activity (Fig. 4A) . Other important aspects for FIG 4 Purification, stability, and conservation of CCHF tc-VLPs. A large stock of tc-VLPs was generated as described for Fig. 1 , using the vL-Ren minigenome.
Differently prepared or treated tc-VLP preparations were used to infect HuH-7 indicator cells expressing CCHFV L and N. REN-Luc was measured 24 h postinfection and normalized on the inactive L polymerase (L⌬DD) supernatant condition, and the activity was expressed as a percentage of the fresh and crude REN-VLP supernatant condition. Mean values and the standard deviations of 3 independent experiments are shown. A two-tailed, paired t test was used to compare the treated supernatants with the untreated one. (A) REN-Luc activity in cells infected with either crude, ultracentrifuged, ultracentrifuged through a sucrose cushion, or PEG-precipitated tc-VLPs. The 100-fold-concentrated tc-VLPs were diluted 100-fold for the luciferase assay. (B) REN-Luc activity in cells infected with crude tc-VLP supernatants used immediately after collection (fresh), stored for 3 days at different temperatures, or incubated for 10 min at 95°C. One tc-VLP sample was frozen (Ϫ80°C) and thawed (RT) 3 times (Fr/th). (C) REN-Luc activity in cells infected with crude tc-VLP supernatants that were stored for 1 year at Ϫ80°C. (D) REN-Luc activity in cells infected with crude tc-VLP supernatants frozen at Ϫ20°C or Ϫ80°C for 3 days in the presence of various additives. Some samples were also frozen (Ϫ80°C) and thawed (RT) 3 times (Fr/th). *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001; n.s., not significant. downstream VLP applications are environmental stability and shelf life. To determine the stability, we incubated VLPs for 3 days at either 37°C, room temperature, ϩ4°C, Ϫ20°C, or Ϫ80°C. Moreover, we freeze-thawed particle preparations 3 times from Ϫ80°C to room temperature or incubated them for 10 min at 95°C as a negative control. As shown in Fig. 4B , only storage at Ϫ20°C or below was able to preserve VLP quality, whereas any prolonged storage at higher temperatures, as well as repeated freeze-thawing, was detrimental. On the other hand, when kept at Ϫ80°C, even after over a year of storage the VLPs were still active to about 40% (Fig. 4C) . Similar results were obtained with VLPs containing the minigenome with the weak S segment promoter (data not shown). We also tested the influence of various additives known to enhance VLP stability (28, 29) (Fig. 4D) . The presence of DEAEdextran (to dissolve particle aggregates) did not change VLP activity, whereas sucrose (to prevent conformational changes of viral envelope proteins) decreased REN-Luc activity similarly to lysine or the detergent Tween 20, either of which is known to disrupt VLP structure. Apparently, for unknown reasons the presence of glycerol or sorbitol (reducer of protein aggregation and stabilizer of VLP tertiary structure, respectively) not only preserved but slightly increased REN-Luc activity, although this was not statistically significant (Fig. 4D) . Thus, the CCHF tc-VLPs can be stored for a long time at Ϫ80°C without any major degradation, either crude or in the presence of glycerol or sorbitol solutions.
Endonuclease domain of CCHFV. Bunyaviruses share with arenaviruses and orthomyxoviruses the ability to cleave host cell mRNAs and use the resulting 5= capped oligonucleotides as primers for their own transcription ("cap-snatching"). The viral endonuclease domains had been identified and the atomic structures had been solved for arenaviruses (21) , orthomyxoviruses (30, 31) , and the bunyavirus LACV (32) . The endonuclease domain of LACV (genus Orthobunyavirus) is situated at the N terminus of the L protein. Sequence alignments indicated a similar N-terminal endonuclease domain for three other Bunyaviridae genera, Phlebovirus, Hantavirus, and Tospovirus (32), and for phleboviruses, this was confirmed by functional data (21, 22) . For the genus Nairovirus (to which CCHFV belongs), however, the N terminus of the L protein harbors the so-called OTU domain, which has immune escape function (33) . Morin et al. proposed that the endonuclease domain of nairoviruses is located further downstream (Fig. 5A) , since the amino acid sequence and predicted structure around position 700 exhibit similarities to the N terminus of the other bunyaviruses (21) (Fig. 5B) . We employed our tc-VLP production/infection system to test this hypothesis. The predicted -SV40) , and the RdRp-inactive mutant L_⌬DD were used as controls. Note that the amount of the negative-sense vL_Ren minigenome plasmid was lowered to 10 ng per well to reduce the RT-PCR background signal. rel., relative. Mean values and the standard deviations of 4 independent experiments are shown. A two-tailed, paired t test was used to compare the mutant polymerase activity to the wild-type polymerase activity. **, P Ͻ 0.01; ***, P Ͻ 0.001; n.s., not significant. endonuclease-signature amino acids 693, 718, and 734 of CCHFV L were individually exchanged against alanine. In donor cells producing VLPs, this resulted in a substantial impact on reporter activity, with mutants D693A and K734A not displaying any activity and D718A being down to one-fourth of wild-type (wt) activity (Fig. 5C) . However, when supernatants of the donor cells were transferred on indicator cells that express wt L (together with N), all mutants could be rescued to some extent (Fig. 5D) . VLPs of mutant D693A were even transcomplemented to an activity level that slightly (though not significantly) exceeded that of wt VLPs. The results indicate that transcription-inactive nucleocapsids of mutant D693A had been assembled, replicated, and packaged into VLPs. Indeed, direct analysis of RNA synthesis by strand-specific real-time RT-PCR of donor cells revealed that the D693A mutant, which did not generate translatable reporter mRNA (Fig. 5C) , produced substantial amounts of positive-strand RNA (Fig. 5E ). This indicates unhindered production of cRNA, i.e., minigenome replication. The other two mutants exhibited a similar correlation between positive-strand RNA synthesis and the ability to be transcomplemented ( Fig. 1D ) but had a slightly (D718A) or significantly (K734A) lower rate of RNA synthesis, making it difficult to draw firm conclusions. Thus, mutant D693A displays the most striking phenotype, with a complete lack of mRNA transcription but an uninhibited RNA replication activity. These results demonstrate that D693 in the CCHFV L sequence is needed for mRNA transcription but not for genome replication, indicating that the surrounding domain is indeed harboring the predicted endonuclease domain (21) .
Taken together, the results show that our tc-VLP system is a suitable tool to investigate aspects of CCHFV biology such as neutralizing antibody responses, cell infection, mRNA transcription, and genome replication under convenient BSL-2 conditions. DISCUSSION tc-VLP systems and minireplicons are useful tools for studying and dissecting individual steps of the viral multiplication cycle. In the case of CCHFV as well as of other highly pathogenic viruses (18, 20, 22, 34, 35) , they confer the additional advantage of abrogating the need for high-containment facilities, since they are nonmultiplying and lack authentic virus genes (8) . CCHFV tcVLPs were capable of primary transcription, which is detectable when the REN-Luc reporter is expressed via the strong L segment promoter. This demonstrates that the L polymerase packaged into the VLPs is active and confirms previous observations on the high activity of the bunyaviral L promoter (14, 16, 36, 37) . Using a tc-VLP system for RVFV, we have previously shown that primary transcription is sufficient to trigger innate immune responses mediated by the pathogen recognition receptor RIG-I (38) and that the antiviral host cell protein MxA is targeting RVFV primary transcription (18) . Given that the CCHFV genome is lacking the RIG-I-activating 5= triphosphate group (39) and that CCHFV is also inhibited by MxA (40), the tc-VLPs presented here will complement the set of available systems to study and compare bunyavirus biology with respect to antiviral responses, requirements for RIG-I activation, and transcription activity.
Expression of the nucleocapsid proteins L and N in trans strongly increased reporter activity by tc-VLPs, indicating a switch to genome replication mode. Moreover, the additional supply of GPs further increased reporter activity and led to formation of second-generation VLPs that reinfected the cells. Consequently, repeated passaging of tc-VLPs allowed us to substantially increase VLP yields. To eliminate the need for repeated plasmid transfections, we are aiming toward the generation of a packaging cell line expressing all structural proteins, similar to what was reported for RVFV (27) .
VLPs are used for numerous downstream applications, e.g., diagnostics and vaccines. For this, it is important to purify, concentrate, and store them without losing stability. Purification by polyethylene glycol (PEG) precipitation or by ultracentrifugation through a sucrose cushion allows concentration of the VLPs without substantial loss of activity. Biological activity was also maintained after freezing the crude VLP supernatants at Ϫ20°C or Ϫ80°C for 3 days, whereas positive temperatures were destructive. At Ϫ80°C, the crude VLPs could be frozen for longer periods without losing much activity.
Direct diagnosis of CCHFV infection is based either on virus isolation or on molecular detection of the genome (41) (42) (43) (44) (45) . However, the period in which the virus can be detected in patients is rather short. Therefore, most of the current diagnostic assays are based on serology. Indirect immunofluorescence assays (IFAs) and enzyme-linked immunosorbent assays (ELISAs) are the most reliable and useful methods, since they can detect and differentiate IgM and IgG antibodies (46) . Inactivated CCHFV particles are expected to be the best material for such assays, but they require a BSL-4 facility to produce. Our structurally similar tc-VLPs provide a useful alternative, as attested by the presented assay to determine neutralizing antisera.
The tc-VLP production/infection system allowed us to verify the prediction by Morin et al. that the endonuclease domain of nairoviruses is located around amino acid D693 in the L sequence (21) . The L alanine-substitution mutant at this position has entirely lost the ability to transcribe mRNA but has retained the ability to replicate the minigenome and assemble nucleocapsids that could be packaged into virions. D693 coaligns with D79 of LACV, D111 of RVFV, and D89 of arenaviruses. Mutants of these corresponding amino acids were shown to display a selective loss of transcription activity similar to that of CCHFV L D693A (21, 22, 32) . It is hence likely that D693 inhabits the same key position in the active center and complexes the two Mn 2ϩ ions that are necessary for endonucleolytic cleavage of host mRNAs. The D693A mutant will now enable us to study the RNA replication activity of CCHFV independently of mRNA transcription.
In summary, we have established a tc-VLP system which enables studies of the CCHFV infection cycle under BSL-2 conditions and may help to develop vaccines and antivirals. We are confident that this system will accelerate future research on the highly pathogenic CCHFV.
